^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors
Published date:
05/07/2021
Excerpt:
There were 141 patients (8.5%) with BRCA1/2 alteration in the MSKCC immunotherapy cohort...Patients with BRCA2 altered tumors had better OS than those without (median [IQR] OS, 31.0 [10.0-80.0] months vs 18.0 [6.0-58.0] months; P = .02)...
DOI:
10.1001/jamanetworkopen.2021.7728
